Project Grant 2036233
Award Date
4/1/21
Completion Date
3/31/22
Dollars Obligated
$256K
Federal Agency
Division of Industrial Innovation
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...
Spirrow Therapeutics LLC received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation under the Engineering program (CFDA 47.041) to develop polymer surfactant therapy for acute respiratory distress syndrome (ARDS), including that caused by COVID-19. The grant period runs from February 15, 2021 through January 31, 2022. The NSF Engineering program seeks to improve quality of life and economic strength through engineering research and...
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Altay Therapeutics, Inc., a biotechnology company, to develop novel small molecule therapies that target disease-causing transcription factors for treating chronic illnesses and cancers. The key goals of this SBIR Phase I project are to: (1) determine the toxicity profile of new inhibitors across human cells, (2) measure drug specificity to the target...
This Project Grant from the National Science Foundation (NSF) Engineering program (CFDA 47.041) provided $255,943 to Athem LLC from February 15, 2021 through March 31, 2022. The grant funded the development of a medical device to isolate and purify therapeutic antibodies from recovered COVID-19 donors. The NSF Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award aimed to advance those goals by...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
The National Science Foundation awarded Ancilia, Inc. a $255,717 Small Business Technology Transfer Phase I Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant will support development of phage-resistant bacterial therapeutics from July 2021 through June 2023. The NSF Technology, Innovation, and Partnerships program seeks to advance science, engineering, and technology innovation to address national challenges. Under this award, Ancilia...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...